Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
about
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerCombination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerSequential versus combination chemotherapy for advanced colorectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerCombination chemotherapy versus single agent chemotherapy during preoperative chemoradiation for resectable rectal cancerAnti-angiogenic therapies for metastatic colorectal cancerChemotherapy with Camptothecin compounds for metastatic colorectal cancerAnti-angiogenic therapy for metastatic colorectal cancerDigital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patientsTumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancerAdjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled studyUGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancerSurgical resection of hepatic metastases from colorectal cancer: a systematic review of published studiesFully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancersPhase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinomaPhase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerIrinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancerRaltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapyExpression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identificationPhase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resectionTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraChemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapyPharmacologic resistance in colorectal cancer: a reviewHepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancerMass Spectrometry-Based N-Glycomics of Colorectal CancerTropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancerIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesAddition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroupsManagement of colorectal cancerFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyPulmonary metastasectomy for colorectal cancer: how many nodules, how many times?Imaging of complications of oncological therapy in the gastrointestinal systemReview of systemic therapies for locally advanced and metastatic rectal cancerManagement of locally advanced and metastatic colon cancer in elderly patientsMolecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 ToxicityCDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
P2860
Q24186145-F80B5C17-167A-4C4D-809D-288134738AD6Q24186443-C76B7EE4-E58B-4F18-B228-C548ED5A386FQ24200737-FBAC5FFD-6F3A-4B99-8671-558555078CC1Q24234461-AD2AF897-92B3-41AE-A8AD-FF83B32E2AE3Q24234555-48756CD9-EC3B-4348-A634-72F2E80456B9Q24235103-360AB134-2154-4FBA-8829-29125295B0D6Q24241813-14E0D987-F303-4F37-81AA-8EC7E2ECFD6DQ24242475-AF3267DE-CCAE-4F97-A245-47D50543CE01Q24243297-6DEE6877-E502-453A-8EB7-C2E20EA7B1B0Q24561669-CAA8B464-0E6D-482E-AE43-C7AE5D72BF6BQ24614511-956B5222-57E9-4642-8368-FF35213174CFQ24645666-066625C5-04F3-4505-889F-A04389CB3A32Q24648015-7662110E-A7F7-4ACB-B0D6-05BEB40FB667Q24651894-53952286-8CD7-4769-995F-8876F3667F98Q24792155-986DC434-75E0-41C4-B740-71C339A6A99EQ24792609-E16DFB69-15FA-4716-A92D-6EC064434B66Q24795149-F93DE1C8-A4D9-4AF8-AEAC-3155C9D16A3BQ24795784-390E9B24-FF55-45CD-8545-2026DE0C6F97Q24801466-3BAAF3A3-D3AF-49CB-A02C-09BAAB338710Q24806443-D18568BB-5CFB-4784-956E-EC52D441882DQ25256709-06318899-9680-4C28-A665-B6BF57058D57Q25257549-622A2303-E320-42E3-9F4F-93E8189C6151Q26745686-1CDF0F57-47F9-4913-9B50-BC10C462B704Q26751344-760EC4A5-47BF-467F-A0A0-0B600CBB1B73Q26768402-A1184C52-231D-4A4A-99B1-71C5DD032D13Q26769850-D28D926A-47C4-414D-9F95-62951BBF7707Q26772267-E3631DFC-353E-4770-A68F-747B8D9CEBB3Q26774414-964FFDE3-85A5-437D-B644-68FC765CD264Q26774713-C3DA7F10-1374-4AEE-BBA4-8810562C5FCCQ26775949-94B14966-7331-47A2-9019-E0C6CA1A87DEQ26795558-C1397626-D784-42B9-B080-365E2A6D9F4BQ26822395-36820514-F836-44A2-9745-7D1FEF621928Q26823550-E697C99D-8D1C-41C7-A59C-9357276F26FFQ26851060-F61363CC-AA0F-4A51-A71C-4D1B6205EDE1Q26859632-7F19C803-DD93-4C93-8454-BF3567BD0088Q27004641-0BDAF34C-AAA4-4AEE-A62A-C8F3B9647B9EQ27021105-EFAD775D-52CF-4D15-9C73-5B3487E3A490Q27026129-4C9CAAC2-1185-4E35-8A57-0E038631F63CQ27678202-5174DC09-DBEA-4C39-82FA-0FF9F7F0E13EQ27853326-06A0EA6C-AA1E-49EF-8AD7-F3822C0930D2
P2860
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@ast
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@en
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@nl
type
label
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@ast
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@en
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@nl
prefLabel
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@ast
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@en
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@nl
P2093
P1476
Irinotecan plus fluorouracil a ...... ancer. Irinotecan Study Group.
@en
P2093
G L Elfring
J A Maroun
L Fehrenbacher
L L Miller
P304
P356
10.1056/NEJM200009283431302
P407
P577
2000-09-01T00:00:00Z